TORL-5-700 in relapsed or refractory B-cell non-Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 1/2 interventional study evaluating TORL-5-700 as a single agent and in combination for relapsed or refractory B-cell non-Hodgkin lymphoma. The trial aims to determine safety, tolerability, and anticancer activity, including identifying the maximum tolerated dose and recommended phase 2 dose. Eligible participants have confirmed B-cell NHL types such as DLBCL, FL, MCL, transformed lymphoma, and related subtypes, with measurable disease and adequate organ function. Exclusions include T-cell lymphomas, certain aggressive B-cell subtypes, CNS involvement, significant neuropathy, and uncontrolled illnesses. The study is led by TORL Biotherapeutics, with locations in California (Fullerton, Los Alamitos, and Santa Monica).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
* At least 1 measurable lesion per Lugano criteria.
* Tumor tissue is available.
* Adequate organ function

Exclusion Criteria:

* T-cell lymphoma
* CLL or SL
* Burkitt lymphoma and high-grade B-cell lymphoma
* CNS involvement
* Peripheral neuropathy \> Grade 2
* Uncontrolled medical conditions
* Viral infections

Where it's running

• Providence Medical Foundation
  Fullerton, California, United States Recruiting
• Cancer and Blood Specialty Clinic, Los Alamitos
  Los Alamitos, California, United States Recruiting
• UCLA
  Santa Monica, California, United States Recruiting
• Stanford University
  Stanford, California, United States Recruiting
• University of California Miami, Sylvester Comprehensive Cancer Center
  Miami, Florida, United States Recruiting
• University of Iowa Health Care
  Iowa City, Iowa, United States Recruiting

Study contacts

• Study coordinator: Eric Park, M.D.
• Email: eric.park@torlbio.com
• Phone: (310) 598-5969

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Giving TORL-1-23 with chemotherapy before initial surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer

  This study will test whether adding TORL-1-23 to standard paclitaxel and carboplatin before initial surgery helps women with advanced (FIGO III/IV) ovarian, fallopian tube, or primary peritoneal cancer whose tumors are CLDN6-positive.

  Recruiting at 7 sites Phase 1/2 TORL Biotherapeutics, LLC · Fullerton, California and 6 other locations · NCT07322094

• Evaluating TORL-1-23 for advanced platinum-resistant ovarian cancer

  This study is testing a new treatment called TORL-1-23 for women with advanced ovarian cancer that doesn't respond to standard platinum-based therapies to see if it can help them.

  Recruiting at 66 sites Phase 2 TORL Biotherapeutics, LLC · Phoenix, Arizona and 65 other locations · NCT06690775

• Testing TORL-1-23 in patients with advanced cancer

  This study is testing a new treatment called TORL-1-23 to see if it can help people with advanced cancers like ovarian, endometrial, and lung cancer feel better and fight their disease.

  Recruiting at 14 sites Phase 1 TORL Biotherapeutics, LLC · Fullerton, California and 13 other locations · NCT05103683

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.